MycoBiomDB – Record Details (MyCo_3712)

Biomarker Record Details

Database ID: MyCo_3712
DB IDMyCo_3712
TitleWhat's new in invasive pulmonary aspergillosis in the critically ill
Year2014
PMID24647810
Fungal Diseases involvedInvasive pulmonary aspergillosis
DiseaseAspergillosis (Aspergillus Infection)
Associated Medical ConditionNone
GenusAspergillus
Speciesspp.
OrganismAspergillus spp.
Ethical StatementNone
Site of InfectionUnspecified
Opportunistic invasiveInvasive/Opportunistic
Sample typeBody fluid
Sample sourceBronchoalveolar lavage fluid (BALF)
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameGM
Biomarker Full NameGalactomannan
Biomarker TypeDiagnostic
BiomoleculeProtein
Geographical LocationMulti-Location
CohortNone
Cohort No.None
Age GroupNone
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismInvasive pulmonary aspergillosis (IPA) has been increasingly recognized as an emerging and understudied opportunistic infection in critically ill patients without classic host factors reflecting profound immunosuppres- sion as defined by the European Organization for the Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG). Impaired immune response fol- lowing critical illness and particular underlying conditions put patients at risk of IPA. Predisposing conditions frequently met in intensive care units (ICUs) include chronic obstructive pulmonary disease (COPD), corticosteroid (CS) use, decompensated liver disease, acute respiratory distress syndrome (ARDS), severe sep-sis, post-sepsis immunoparalysis, and H1N1 virus infection (especially if CS prior to ICU admission).
Sub TechniqueLateral flow
TechniqueImmunoassay
Analysis MethodGM Assay
ELISA kitsNone
Assay DataNone
Validation Techniques usedGM Assay
Up Regulation Down RegulationPositive
Sequence DataNone